Persistence of antibiotic resistant bacteria

Current Opinion in Microbiology

Volumn 6, Issue 5, 2003, Pages 452-456

  Andersson, Dan I ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL MUTATION; GENETIC LINKAGE; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0242323604     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2003.09.001     Document Type: Review

References (39)

1. Visser JA: The fate of microbial mutators. Microbiology 2002, 148:1247-1252.
2. Oliver A, Canton R, Campo P, Baquero F, Blazquez J: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1254.
3. Björkholm B, Sjolund M, Falk PG, Berg OG, Engstrand L, Andersson DI: Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori. Proc Natl Acad Sci USA 2001, 98:14607-14612. This study suggests that the costs of clarithromycin resistance can be rapidly (within three months) compensated when the bacteria grow in a human stomach.
4. Denamur E, Bonacorsi S, Giraud A, Duriez P, Hilali F, Amorin C, Bingen E, Andremont A, Picard B, Taddei F, Matic I: High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 2002, 184:605-609.
5. Boe L, Danielsen M, Knudsen S, Petersen JB, Maymann J, Jensen PR: The frequency of mutators in populations of Escherichia coli. Mutat Res 2000, 448:47-55.
6. Tanabe K, Kondo T, Onodera Y, Furusawa M: A conspicuous adaptability to antibiotics in the Escherichia coli mutator strain, dnaQ49. FEMS Microbiol Lett 1999, 176:191-196.
7. Schaaff F, Reipert A, Bierbaum G: An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002, 46:3540-3548.
8. Giraud A, Matic I, Radman M, Fons M, Taddei F: Mutator bacteria as a risk factor in treatment of infectious diseases. Antimicrob Agents Chemother 2002, 46:863-865.
9. Mao EF, Lane L, Lee J, Miller JH: Proliferation of mutators in a cell population. J Bacteriol 1997, 179:417-422.
10. McKenzie GJ, Rosenberg SM: Adaptive mutations, mutator DNA polymerases and genetic change strategies of pathogens. Curr Opin Microbiol 2001, 4:586-594.
11. Roth JR, Kofoid E, Roth FP, Berg OG, Seger J, Andersson DI: Regulating general mutation rates. Examination of the hypermutable state model for cairnsian adaptive mutation. Genetics 2003, 163:1483-1496.
12. Hendrickson H, Slechta ES, Bergthorsson U, Andersson DI, Roth JR: Amplification-mutagenesis: evidence that 'directed' adaptive mutation and general hypermutability result from growth with a selected gene amplification. Proc Natl Acad Sci USA 2002, 99:2164-2169. This study provides strong evidence that selective gene amplification of the mutated lac operon is required for adaptive reversion to occur.
13. Slechta ES, Harold J, Andersson DI, Roth JR: The effect of genomic position on reversion of a lac frameshift mutation (lacIZ33) during non-lethal selection (adaptive mutation). Mol Microbiol 2002, 44:1017-1032.
14. Slechta ES, Liu J, Andersson DI, Roth JR: Evidence that selected amplification of a bacterial lac frameshift allele stimulates Lac(+) reversion (adaptive mutation) with or without general hypermutability. Genetics 2002, 161:945-956.
15. Kofoid E, Bergthorsson U, Slechta ES, Roth JR: Formation of an F′ plasmid by recombination between imperfectly repeated chromosomal Rep sequences: a closer look at an old friend (F′(128) pro lac). J Bacteriol 2003, 185:660-663.
16. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI: Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 2000, 287:1479-1482.
17. Ysern P, Clerch B, Castano M, Gibert I, Barbe J, Llagostera M: Induction of SOS genes in Escherichia coli and mutagenesis in Salmonella typhimurium by fluoroquinolones. Mutagenesis 1990, 5:63-66.
18. Ren L, Rahman MS, Humayun MZ: Escherichia coli cells exposed to streptomycin display a mutator phenotype. J Bacteriol 1999, 181:1043-1044.
19. Levin BR: Models for the spread of resistant pathogens, Net J Med 2002, 60:58-64.
20. Austin DJ, Kristinsson KG, Anderson RM: The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999, 96:1152-1156.
21. Cohen T, Sommers B, Murray M: The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003, 3:13-21. This is a very nice and exhaustive review of the effects of drug resistance on the fitness of M. tuberculosis, in particular the discussion of various epidemiological approaches to estimate fitness costs.
22. Davies AP, Billington OJ, Bannister BA, Weir WR, McHugh TD, Gillespie SH: Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment. J Infect 2000, 41:184-187.
23. Laurent F, Lelievre H, Cornu M, Vandenesch F, Carret G, Etienne J, Flandrois JP: Fitness and competitive growth advantage of new gentamicin-susceptible MRSA clones spreading in French hospitals. J Antimicrob Chemother 2001, 47:277-283.
24. Billington OJ, McHugh TD, Gillespie SH: Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999, 43:1866-1869.
25. Levin BR, Perrot V, Walker N: Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 2000, 54:985-997.
26. Reynolds MG: Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 2000, 156:1471-1481.
27. Massey RC, Buckling A, Peacock SJ: Phenotypic switching of antibiotic resistance circumvents permanent costs in Staphylococcus aureus. Curr Biol 2001, 11:1810-1814.
28. Nagaev I, Björkman J, Andersson DI, Hughes D: Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol Microbiol 2001, 40:433-439.
29. Johnsen PJ, Simonsen GS, Olsvik O, Midtvedt T, Sundsfjord A: Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci in the absence of antibiotic selection in vitro and in mice. Microb Drug Resist 2002, 8:161-170.
30. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI: Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol Microbiol 2002, 46:355-366. This study shows that the fitness cost of a specific rpsL mutation causing streptomycin resistance can be compensated by an unexpected variety of mutations.
31. Pym AS, Saint-Joanis B, Cole ST: Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002, 70:4955-4960.
32. Sanchez P, Linares JF, Ruiz-Diez B, Campanario E, Navas A, Baquero F, Martinez JL: Fitness of in vitro selected Pseudomonas aeruginosa naIB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002, 50:657-664.
33. Sander P, Springer B, Prammananan T, Sturmfels A, Kappler M, Pletschette M, Bottger EC: Fitness cost of chromosomal drug resistance-conferring mutations. Antimicrob Agents Chemother 2002, 46:1204-1211.
34. Wichelhaus TA, Boddinghaus B, Besier S, Schafer V, Brade V, Ludwig A: Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Agents Chemother 2002, 46:3381-3385.
35. Gillespie SH, Voelker LL, Dickens A: Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 2002, 8:79-84.
36. Gustafsson I, Cars O, Andersson DI: Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers. J Antimicrob Chemother 2003, 52:258-263.
37. Lipsitch M, Bergstrom CT, Levin BR: The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proc Natl Acad Sci USA 2000, 97:1938-1943.
38. Seppala H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P: The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997, 337:441-446.
39. Enne VI, Livermore DM, Stephens P, Hall LM: Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001, 357:1325-1328. A depressing illustration of the unlikelyness of reversibility of antibiotic resistance. This report shows that after a drastic reduction in the use of sulphonamide in the UK from 1991 to 1999 the frequency of sulphonamide resistant E. coli, instead of decreasing, actually increased slightly from 40 to 46%. The reason for this is most likely that the sulphonamide resistance gene is genetically linked to other resistance genes that have been continuously selected.